VERTEX PHARMACEUTICALS INC / MA
Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.
CAPITALIZATION 12/31/25
| ($ millions) | Amount | % |
|---|---|---|
| Total debt | – | – |
| Stockholders' equity | 18,666 | 100.0 |
| Total capitalization | 18,666 | 100.0 |
253,460,924 shares outstanding at 31 July 2026 (cover page of the 10-Q filed 4 August 2026).
LONG-TERM DEBT 12/31/25
| ($ millions) | Amount |
|---|---|
| Not tagged in XBRL |
CAPITAL STOCK 12/31/25
| Common shares authorized | 500,000,000 |
| Common shares issued | 253,991,224 |
| Par or stated value per share ($) | 0.01 |
| Preferred stock ($ millions) | 0 |
| Outstanding at 7/31/26 | 253,460,924 |
DIVIDENDS DECLARED/PAID
| Fiscal year | Per share $ | Payout % |
|---|---|---|
| 2025 | – | – |
| 2024 | – | – |
| 2023 | – | – |
| 2022 | – | – |
| 2021 | – | – |
HISTORY AND BUSINESS
HISTORY: Incorporated in Massachusetts.
BUSINESS: Classified by the SEC under Standard Industrial Classification 2834, Pharmaceutical Preparations. Large accelerated filer. Principal executive office: 50 Northern Avenue, Boston, MA 02210. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.
CONSOLIDATED INCOME ACCOUNT, YEARS ENDED
| ($ millions) | 12/31/25 | 12/31/24 | 12/31/23 |
|---|---|---|---|
| Revenues | 12,001 | 11,020 | 9,869 |
| Cost of revenues | 1,651 | 1,530 | 1,262 |
| Research and development | 3,910 | 3,630 | 3,163 |
| Selling, general and administrative | 1,753 | 1,464 | 1,137 |
| Depreciation and amortization | 210 | 207 | 181 |
| Operating income | 4,173 | (233) | 3,832 |
| Interest expense | 13 | 31 | 44 |
| Income before income taxes | 4,643 | 248 | 4,380 |
| Income taxes | 690 | 784 | 760 |
| Net income | 3,953 | (536) | 3,620 |
| Earned per share, diluted ($) | 15.32 | (2.08) | 13.89 |
| Dividends per share ($) | – | – | – |
CONSOLIDATED BALANCE SHEET
| ($ millions) | 12/31/25 | 12/31/24 |
|---|---|---|
| Cash and equivalents | 5,085 | 4,570 |
| Receivables, net | 2,053 | 1,609 |
| Inventories | 1,687 | 1,205 |
| Total current assets | 11,201 | 9,596 |
| Property, plant and equipment, net | 1,520 | 1,228 |
| Goodwill | 1,088 | 1,088 |
| Total assets | 25,643 | 22,533 |
| Total current liabilities | 3,861 | 3,565 |
| Total liabilities | 6,977 | 6,124 |
| Stockholders' equity | 18,666 | 16,410 |
| Total liabilities and equity | 25,643 | 22,533 |
TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)
| Fiscal year ended | Revenues | Oper. income | Net income | Net margin % | EPS diluted $ | Div. per share $ | Oper. cash flow | Capital expend. | Free cash flow | Total assets | Total liabilities | Total debt | Stockholders' equity | ROE % | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/31/25 | 12,001 | 4,173 | 3,953 | 32.9 | 15.32 | – | 3,631 | 438 | 3,194 | 25,643 | 6,977 | – | 18,666 | 21.2 | – |
| 12/31/24 | 11,020 | (233) | (536) | -4.9 | (2.08) | – | (493) | 298 | (790) | 22,533 | 6,124 | – | 16,410 | -3.3 | – |
| 12/31/23 | 9,869 | 3,832 | 3,620 | 36.7 | 13.89 | – | 3,537 | 200 | 3,337 | 22,730 | 5,150 | – | 17,580 | 20.6 | – |
| 12/31/22 | 8,931 | 4,307 | 3,322 | 37.2 | 12.82 | – | 4,130 | 205 | 3,925 | 18,151 | 4,238 | – | 13,913 | 23.9 | – |
| 12/31/21 | 7,574 | 2,782 | 2,342 | 30.9 | 9.01 | – | 2,644 | 235 | 2,408 | 13,432 | 3,332 | – | 10,100 | 23.2 | – |
| 12/31/20 | 6,206 | 2,856 | 2,712 | 43.7 | 10.29 | – | 3,254 | 260 | 2,994 | 11,752 | 3,065 | – | 8,687 | 31.2 | – |
| 12/31/19 | 4,163 | 1,198 | 1,177 | 28.3 | 4.51 | – | 1,569 | 75 | 1,494 | 8,318 | 2,233 | – | 6,085 | 19.3 | – |
| 12/31/18 | 3,048 | 635 | 2,097 | 68.8 | 8.09 | – | 1,270 | 95 | 1,175 | 6,246 | 1,811 | – | 4,435 | 47.3 | – |
| 12/31/17 | 2,489 | 123 | 263 | 10.6 | 1.04 | – | 845 | 99 | 746 | 3,546 | 1,504 | – | 2,029 | 13.0 | – |
| 12/31/16 | 1,702 | 10 | (112) | -6.6 | (0.46) | – | 236 | 57 | 180 | 2,897 | 1,559 | – | 1,157 | -9.7 | – |
Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.
REGISTRANT:
VERTEX PHARMACEUTICALS INC / MA
CIK 875320 · EIN 04-3039129
PRINCIPAL OFFICE:
50 Northern Avenue, Boston, MA 02210
Tel.: 6173416393
INCORPORATED:
Massachusetts
INDUSTRY (SEC SIC CODE):
2834 · Pharmaceutical Preparations
FILER STATUS:
Large accelerated filer
LATEST ANNUAL REPORT:
10-K for period ended 12/31/25, filed 13 February 2026
Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/13/26) · 10-K FY2024 (filed 2/13/25) · 10-K FY2023 (filed 2/15/24) · 10-K FY2022 (filed 2/10/23) · 10-K FY2021 (filed 2/9/22) · 10-K FY2020 (filed 2/11/21) · 10-K FY2019 (filed 2/13/20) · 10-K FY2018 (filed 2/13/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.
Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.